



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

## REC: CardioClinics

www.reccardioclinics.org



## Original article

# Influence of cardiovascular disease and cardiovascular risk factors in COVID-19 patients. Data from a large prospective Spanish cohort

Marcos García-Guimaraes<sup>a,b,c,\*</sup>, Diana Mojón<sup>a,b,◇</sup>, Alicia Calvo<sup>a,b</sup>, Andrea Izquierdo<sup>a,b</sup>, Laia Belarte-Tornero<sup>a,b</sup>, Neus Salvatella<sup>a,b</sup>, Marc Llagostera<sup>a,b</sup>, Alejandro Negrete<sup>a,b</sup>, Aleksandra Mas-Stachurska<sup>a,b</sup>, Sonia Ruiz<sup>a,b</sup>, Sandra Valdivielso<sup>a,b</sup>, Nuria Ribas<sup>a,b</sup>, Jaume Marrugat<sup>b</sup>, Nuria Farré<sup>a,b</sup>, Beatriz Vaquerizo<sup>a,b</sup>

<sup>a</sup> Servicio de Cardiología, Hospital del Mar, Barcelona, Spain

<sup>b</sup> Grup de Recerca Biomèdica en Malalties del Cor, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain

<sup>c</sup> Department of Cardiovascular Sciences and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, United Kingdom

## ARTICLE INFO

## Article history:

Received 16 September 2020

Accepted 12 November 2020

Available online 17 November 2020

## Keywords:

Cardiovascular disease

Cardiovascular risk factors

Heart failure

COVID-19

SARS-CoV-2

## ABSTRACT

**Introduction and objectives:** Coronavirus disease 2019 (COVID-19) has become a pandemic. Retrospective data showed worse outcomes in patients with cardiovascular disease (CVD) and cardiovascular (CV) risk factors. Our aim was to evaluate the link between CVD and CV risk factors and in-hospital outcomes in COVID-19 patients.

**Methods:** We designed a prospective registry that included consecutive COVID-19 patients admitted at our institution. The inclusion period was from 27 February to 7 April 2020. Clinical outcomes were monitored up to 2 May 2020.

**Results:** A total of 876 patients were included. Mean age was  $62 \pm 18$  years old; 47% were > 65 years of age. A total of 69% of patients had at least one CV risk factor; 15% of the patients had previous history of CVD. Patients with previous CVD were significantly older ( $77 \pm 11$  vs  $60 \pm 18$  years old;  $P < .01$ ), with a higher proportion of men (64 vs 54%;  $P = .021$ ) and showed a higher proportion of rise in both high-sensitivity cardiac-specific troponin-T (hs-cTnT) (78 vs 27%;  $P < .01$ ) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) (74 vs 29%;  $P < .01$ ) on admission. Those patients with CV risk factors were also significantly older ( $68 \pm 16$  vs  $49 \pm 16$  years old;  $P < .01$ ), showing a higher percentage of patients fulfilling acute distress respiratory syndrome criteria (28 vs 21%;  $P = .021$ ) and more need of mechanical ventilation (9 vs 4%;  $P < .01$ ). Levels of hs-cTnT (44 vs 9%;  $P < .01$ ) and NT-proBNP (43 vs 15%;  $P < .01$ ) were more frequently elevated in patients with CV risk factors. Risk of death was significantly

\* Corresponding author.

E-mail address: [marcos.garcia.guimaraes@gmail.com](mailto:marcos.garcia.guimaraes@gmail.com) (M. García-Guimaraes).

◇ Both authors have equally contributed to this paper.

<https://doi.org/10.1016/j.rccl.2020.11.004>

2605-1532/© 2020 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Cardiología.

higher in patients with CVD (33 vs 8%;  $P < .01$ ) or CV risk factors (16 vs 1%;  $P < .01$ ). We found age  $> 65$  years old (OR, 15; 95%CI, 5-43), chronic congestive heart failure (OR, 3.27; 95%CI, 1.38-7.72) and chronic kidney disease (OR, 8.55; 95%CI, 1.47-5.46) as independent predictors of death.

**Conclusions:** In patients admitted for COVID-19, CVD or CV risk factors are associated with an increased risk of death during hospitalization. We found that older age, history of congestive heart failure and chronic kidney disease are independent predictors of death in COVID-19.

© 2020 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Cardiología.

## Influencia de la enfermedad cardiovascular y los factores de riesgo cardiovascular en pacientes con COVID-19: datos de una cohorte prospectiva amplia de pacientes

### R E S U M E N

#### Palabras clave:

Enfermedad cardiovascular  
Factores de riesgo cardiovascular  
Insuficiencia cardiaca  
COVID-19  
SARS-CoV-2

**Introducción y objetivos:** La enfermedad coronavírica de 2019 (COVID-19) se ha convertido en una pandemia. Datos de estudios retrospectivos han mostrado una peor evolución en pacientes con enfermedad cardiovascular (ECV) y factores de riesgo cardiovascular (FRCV). Nuestro objetivo fue evaluar la relación entre la ECV y los FRCV con la evolución hospitalaria de pacientes con COVID-19.

**Métodos:** Se diseñó un registro prospectivo que incluyó a pacientes consecutivos con COVID-19 ingresados en nuestro centro hospitalario. El periodo de inclusión abarcó desde el 27 de febrero al 7 de abril de 2020. Se monitorizaron los eventos clínicos hasta el 2 de mayo de 2020.

**Resultados:** Se incluyó un total de 876 pacientes. La edad media fue de  $62 \pm 18$  años; un 47% fueron  $> 65$  años. Un 69% de los pacientes tenían al menos un FRCV; un 15% tenían ECV previa. Aquellos pacientes con ECV fueron significativamente más mayores ( $77 \pm 11$  frente a  $60 \pm 18$  años;  $p < 0,01$ ), con una mayor proporción de varones (64 frente a 54%;  $p = 0,021$ ) y mostraron en mayor proporción, en el momento del ingreso hospitalario, elevación de troponina T ultrasensible (hs-cTnT) (78 frente a 27%;  $p < 0,01$ ) y de fracción aminoterminal del péptido natriurético cerebral tipo B (NT-proBNP) (74 frente a 29%;  $p < 0,01$ ). Aquellos pacientes con FRCV fueron significativamente más mayores ( $68 \pm 16$  frente a  $49 \pm 16$  años;  $p < 0,01$ ), mostrando un mayor porcentaje de pacientes que cumplían criterios diagnósticos de síndrome de distrés respiratorio agudo (28 frente a 21%;  $p = 0,021$ ) y un mayor porcentaje de necesidad de ventilación mecánica invasiva (9 frente a 4%;  $p < 0,01$ ). Los pacientes con FRCV presentaron con mayor frecuencia elevación de los niveles de hs-cTnT (44 frente a 9%;  $p < 0,01$ ) y NT-proBNP (43 frente a 15%;  $p < 0,01$ ). El riesgo de muerte fue significativamente mayor en los pacientes con ECV (33 frente a 8%;  $p < 0,01$ ) o FRCV (16 frente a 1%;  $p < 0,01$ ). La edad  $> 65$  años (OR = 15; IC95%, 5-43), la insuficiencia cardiaca (OR = 3,27; IC95%, 1,38-7,72) y la insuficiencia renal crónica (OR = 8,55; IC95%, 1,47-5,46) fueron predictores independientes de mortalidad hospitalaria por COVID-19.

**Conclusiones:** En pacientes ingresados por COVID-19, la presencia de ECV o FRCV se asocia con un mayor riesgo de muerte durante la hospitalización. Una mayor edad, la historia de insuficiencia cardiaca y la insuficiencia renal crónica fueron predictores independientes de muerte por COVID-19.

© 2020 Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española de Cardiología.

## Introduction

Coronavirus disease 2019 (COVID-19), produced by a new type of coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a pandemic. Since the first cases described in the Chinese city of Wuhan, province of Hubei, in December 2019, this pathogen has

rapidly spread worldwide. Since 31 December 2019 and as of 2 August 2020, 17 841 669 cases of COVID-19 have been reported worldwide, including 685 281 deaths.<sup>1</sup> The high speed of expansion of this infection has led health-care systems of many countries to a situation close to collapse and to many governments to impose lockdown. Spain has become one of the countries more aggressively affected by this condition, with 288 522 patients confirmed positive and

28445 related deaths.<sup>2</sup> Although the main clinical manifestations of COVID-19 are respiratory, it has been described that some patients develop some degree of cardiovascular (CV) damage.<sup>3</sup> In addition, data from retrospective cohorts of patients with COVID-19 described a tendency to a more aggressive disease and worse outcomes in patients with CV disease (CVD).<sup>3</sup> We aimed to evaluate the link between CVD and CV risk factors and in-hospital outcomes from a prospective cohort of consecutive COVID-19 patients admitted at our institution.

## Methods

### Study design and data collection

We designed a prospective registry that included consecutive laboratory-confirmed COVID-19 patients admitted at our institution. The period of inclusion ranged from 27 February to 7 April 2020. Clinical outcomes were monitored up to 2 May 2020. Demographic characteristics (age and sex), clinical data (both CV and other significant comorbidities, laboratory findings, treatments, complications, and in-hospital outcomes) and results of cardiac examinations (electrocardiography and echocardiography) were collected from medical records and independently entered into a dedicated electronic database. A predefined laboratory test (including a complete blood count, coagulation tests, liver and renal function, electrolytes, C-reactive protein, procalcitonin, lactate dehydrogenase, creatine kinase, D-dimer, NT-proBNP and high-sensitivity cardiac-specific troponin-T (hs-cTnT) was performed on admission. Levels of NT-proBNP and hs-cTnT were measured thereafter if clinically indicated.

This study was performed according the Declaration of Helsinki, ISO 14155, and clinical practice guidelines. The study protocol was approved by the Institutional Ethics Committee and the hospitals' research commissions of our institution. Written informed consent was waived in light of the urgent need to collect data.

### Laboratory tests

Only laboratory-confirmed cases were included. A laboratory-confirmed COVID-19 was defined by a positive result on a reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay of a specimen collected on a nasopharyngeal swab. RT-PCR assays were performed according to World Health Organization interim guidance document.<sup>4</sup>

The electrochemiluminescence-based immunoanalytical system, Elecsys 2010 (Roche Diagnostics Ltd., Germany) was used to determine plasma levels of NT-proBNP and hs-cTnT. Hs-cTnT had a limit of detection of 5 ng/L and a 99 percentile in the healthy population of 14.0 ng/L. The manufacturer recommends a cut-off value for a positive test (for myocardial injury) of 14.0 ng/L.<sup>5</sup> For NT-proBNP, a level  $\geq 300$  pg/mL on the acute setting was considered positive, following European Society of Cardiology recommendations.<sup>6</sup>

### Study definitions

The presence of CV risk factors was defined as the existence of at least one item among hypertension, hyperlipidemia, diabetes, history of smoking or obesity. CVD was defined as the presence of coronary artery disease, chronic congestive heart failure (CHF), valvular heart disease, atrial fibrillation/atrial flutter, stroke or peripheral artery disease. Cardiac injury was diagnosed if serum levels of hs-cTnT were above the 99 percentile upper reference limit, regardless of new electrocardiographic or echocardiographic abnormalities, according to the Fourth Universal Definition of Myocardial Infarction.<sup>7</sup> Acute respiratory distress syndrome (ARDS) was diagnosed according to the Berlin criteria as acute-onset hypoxemia (ratio of arterial oxygen partial pressure to fractional inspired oxygen expressed as a fraction  $[\text{PaO}_2/\text{FiO}_2] < 300$ ) associated with bilateral pulmonary opacities on chest imaging that were not fully explained by CHF or other forms of volume overload.<sup>8</sup>

### Statistical analysis

Quantitative variables are presented as mean  $\pm$  standard deviation or median [interquartile range]. Categorical variables are presented as number (percentage). The Student *t* test or the Mann–Whitney *U* were used to compare continuous variables. Pearson's chi-square test was used for categorical variables.

We designed a multivariable model to find independent predictors of death during hospitalization. To build this model, we analyzed a total of 19 independent variables using a bivariate logistic regression analysis. We included age  $> 65$  years old, sex, CV risk factor (hypertension, hyperlipidemia, diabetes mellitus, smoking habit, obesity), CVD and other significant comorbidities (chronic kidney disease (CKD) – defined as a glomerular filtration rate  $< 60$  mL/min per  $1.73 \text{ m}^2$ , chronic obstructive pulmonary disease (COPD), bronchial asthma and history of previous cancer). We included other 2 variables, active treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), based on previous studies describing their potential role on SARS-CoV-2 mechanisms of infection. For the selection of variables, we used a generous threshold of  $P < .1$  to determine statistical significance to ensure that we did not drop any potentially relevant variable from the final model. Overfitting of the multivariable model was ruled-out on the basis of McFadden's pseudo *R*-squared values and cross-validation method. For the rest of the test, a value of  $P < .05$  was considered statistically significant. All tests were performed with STATA 12 (StataCorp LLC, United States).

## Results


From February 27 to April 7 2020, a total of 876 consecutive patients were included. Baseline characteristics of this population are summarized in Table 1. Mean age was  $62 \pm 18$  years old, men represented 55% of patients included. Almost half of the patients (47%) were  $> 65$  years of age. Fig. 1 shows the distribution of age of the patients included. Sixty-nine percent of patients presented at least one CV risk factor, being hypertension (44%) and hyperlipidemia (32%) the more prevalent.

**Table 1 – Baseline characteristics**

	Total N = 876	≤ 65 years of age (n = 465, 53%)	> 65 years of age (n = 411, 47%)	P
Age, years	62 ± 18	50 ± 12	77 ± 8	< .01
Sex, male	482 (55)	266 (57)	216 (53)	.182
Hypertension	384 (44)	102 (22)	282 (69)	< .01
Dyslipidemia	283 (32)	82 (18)	201 (49)	< .01
Diabetes mellitus	175 (20)	45 (10)	130 (32)	< .01
Smoking habit				< .01
Never	644 (75)	355 (77)	289 (73)	
Active smoker	173 (20)	73 (16)	100 (25)	
Former smoker	37 (4)	31 (7)	6 (2)	
Height, cm	163 ± 10	166 ± 10	161 ± 10	< .01
Weight, kg	77 ± 16	78 ± 17	76 ± 14	.247
BMI, kg/m <sup>2</sup>	29 ± 6	28 ± 6	30 ± 6	.071
Obesity, BMI > 30	159 (18)	78 (21)	81 (24)	.322
≥1 CV risk factor	603 (69)	239 (51)	364 (89)	< .01
Coronary artery disease	62 (7)	8 (2)	54 (13)	< .01
Congestive heart failure	42 (5)	4 (1)	38 (9)	< .01
Valvular heart disease	30 (3)	1 (0.3)	29 (8)	< .01
Atrial fibrillation or atrial flutter	70 (8)	5 (1)	65 (16)	< .01
Previous stroke (ischemic or hemorrhagic)	52 (6)	6 (1)	46 (11)	< .01
Peripheral artery disease	35 (4)	4 (1)	31 (8)	< .01
Cardiovascular disease	135 (15)	17 (4)	118 (29)	< .01
Chronic kidney disease (GFR < 60 mL/min per 1.73 m <sup>2</sup> )	76 (9)	8 (2)	68 (17)	< .01
COPD	67 (8)	13 (3)	54 (13)	< .01
Bronchial asthma	75 (9)	42 (9)	33 (8)	.597
Cirrhosis	11 (1)	7 (2)	4 (1)	.483
Previous cancer	114 (13)	26 (6)	88 (22)	< .01
Active treatment with ACEIs	168 (19)	46 (10)	122 (30)	< .01
Active treatment with ARBs	91 (10)	26 (6)	65 (16)	< .01

ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BMI, body mass index; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate.

Data are expressed as n (%), mean ± SD.



**Fig. 1 – Histogram of age distribution with Kernel density plot.**

The history of smoking (24%), presence of diabetes (20%) or obesity (18%) were less frequent in our cohort. A total of 15% percent of the patients had previous history of CVD. Among them, 7% had coronary artery disease, 5% CHF, 3% significant valvular heart disease and 8% history of atrial fibrillation or

atrial flutter. Other important comorbidities, as CKD (9%) or respiratory disease — COPD in 8% and bronchial asthma in 9% were relatively frequent.

Characteristics at hospital presentation and result of laboratory tests are summarized in [Table 2](#). At presentation, the more frequent sign was the presence of fever (81%), followed by symptoms of cough (72%), dyspnea (41%) and asthenia (35%). Other common symptoms were muscular pain (29%) or diarrhea (22%). Previously described symptoms suggesting SARS-CoV-2 infection as anosmia (12%) or dysgeusia (13%) were relatively unusual in our cohort. A majority of patients (80%) had an abnormal chest X-ray on admission, with one fourth of patients fulfilling criteria of ARDS on admission. Of those patients tested for hs-cTnT and NT-proBNP, 35 and 36% respectively, showed elevated levels of these biomarkers on admission.

The description of management and hospital outcomes of the patients included is summarized in [Table 3](#). A total of 106 patients (12%) required admission to intensive care unit (ICU) of our institution. From the total cohort, almost 2/3 (64%) required some degree of oxygen therapy, with 69 patients (8%) requiring invasive mechanical ventilation. There were no differences in the need for mechanical ventilation between older (age > 65 years) and younger patients (8.3 vs

**Table 2 – Characteristics at presentation and laboratory test results**

	Total N = 876	≤ 65 years of age (n = 465, 53%)	> 65 years of age (n = 411, 47%)	P
Time from symptoms onset to medical attention, days	6 [3–9]	7 [4–9]	5 [3–9]	.124
<i>Signs and symptoms at presentation</i>				
Fever	713 (81)	397 (85)	316 (77)	< .01
Cough	628 (72)	345 (74)	283 (69)	.080
Dyspnea	355 (41)	174 (37)	181 (44)	.046
Chest pain	48 (6)	34 (8)	14 (4)	.011
Muscle pain	253 (29)	165 (35)	88 (21)	< .01
Headache	130 (15)	93 (20)	37 (9)	< .01
Anosmia	105 (12)	80 (17)	25 (6)	< .01
Dysgeusia	115 (13)	78 (17)	37 (9)	< .01
Asthenia	303 (35)	160 (34)	143 (35)	.905
Syncope	12 (1)	4 (1)	8 (2)	.167
Diarrhea	193 (22)	111 (24)	82 (20)	.162
Temperature, Celsius	37 [36.2–37.8]	37 [36.2–37.8]	37 [36.2–37.8]	.964
Systolic blood pressure (mmHg)	128 [116–140]	126 [115–137]	130 [117–143]	< .01
Diastolic blood pressure (mmHg)	76 [68–86]	79 [70–88]	74 [64–84]	< .01
Heart rate (bpm)	89 [78–102]	95 [83–106]	86 [73–98]	< .01
Respiratory rate	23 [20–28]	22 [18–28]	24 [20–28]	.012
O <sub>2</sub> saturation (%)	96 [94–98]	97 [95–98]	95 [92–97]	< .01
Initial PaO <sub>2</sub> /FiO <sub>2</sub>	311 [196–366]	331 [245–381]	282 [165–343]	< .01
Abnormal chest X-ray	700 (80)	358 (77)	342 (83)	.074
ARDS criteria on admission	223 (25)	86 (18)	137 (33)	< .01
Initial C-reactive protein (mg/dL)	6.4 [2.6–13]	4.5 [1.7–10.1]	8.9 [4–15.7]	< .01
Initial lactic acid (mmol/L)	1.3 [1–1.6]	1.2 [0.9–1.5]	1.4 [1–1.8]	.217
Leucocytes (×1000/μL)	6.1 [4.9–8.2]	5.9 [4.7–7.9]	6.4 [5–8.6]	< .01
Initial D-dimer (mcg/L)	670 [420–1120]	530 [350–800]	870 [570–1600]	< .01
Maximal D-dimer (mcg/L)	1175 [655–3355]	920 [495–2545]	1610 [900–3770]	.030
Initial hs-cTnT (ng/L)	0 [0–19]	0 [0–13]	18 [0–33]	< .01
Maximal hs-cTnT (ng/L)	20 [14–46]	14 [0–19]	26 [16–59]	< .01
hs-cTnT elevation on admission	229/656 (35)	26/332 (8)	203/324 (63)	< .01
Initial NT-proBNP (pg/mL)	160 [42–495]	44 [18–123]	457 [197–1436]	< .01
Maximal NT-proBNP (pg/mL)	381 [139–1271]	161 [69–484]	599 [287–2883]	< .01
NT-proBNP elevation on admission	187/506 (36)	27/254 (11)	160/252 (63)	< .01

ARDS, acute distress respiratory syndrome, hs-cTnT, high-sensitivity cardiac-specific troponin-T; NT-proBNP, N-terminal pro-B-type natriuretic peptide.  
Data are expressed as n (%), mean ± SD or median [IQR].

7.5%;  $P = .683$ ). Of the subgroup of patients that required mechanical ventilation, 41 patients (59%) needed prone ventilation. Regarding medical treatment, the drugs more often used were hydroxychloroquine (89%), azithromycin (88%) and ceftriaxone (56%). The drug combination of lopinavir-ritonavir (13%) or tocilizumab (14%) were also quite frequently used. Only 4 patients were treated with remdesivir. Almost one third (32%) of patients received systemic corticosteroid therapy, and 60% received anticoagulation with low-molecular weight heparin (49% receiving prophylactic doses and 11% receiving therapeutic doses). Median length of stay was 9 days [IQR 3–17]. A total of 103 patients (12%) died during admission. In a vast majority of cases (92%) the cause of death was respiratory, with only 7 patients dying from CV causes. In our cohort, CV complications were relatively infrequent, with 33 patients (4%) developing CHF and 21 patients (2%) having pulmonary embolism. Only 1 patient developed drug-induced long-QT ventricular arrhythmia.

The comparison between patients with and without CVD and CV risk factors are summarized in [Table 4](#) and [Table 5](#).

Those patients with previous CVD were significantly older ( $77 \pm 11$  vs  $60 \pm 18$  years old;  $P < .01$ ), with a higher proportion of men (64 vs 54%;  $P = .021$ ). The group of patients with CVD showed a higher proportion of rise in both hs-cTnT (78 vs 27%;  $P < .01$ ) and NT-proBNP (74 vs 29%;  $P < .01$ ) levels on admission. Risk of death was significantly higher in patients with CVD (33 vs 8%;  $P < .01$ ). Those patients with CV risk factors were also significantly older ( $68 \pm 16$  vs  $49 \pm 16$  years old;  $P < .01$ ) with no differences between sex. This last group showed a higher percentage of patients fulfilling ARDS criteria (28 vs 21%;  $P = .021$ ) and more need of mechanical ventilation (9 vs 4%;  $P < .01$ ). Levels of hs-cTnT (44 vs 9%;  $P < .01$ ) and NT-proBNP (43 vs 15%;  $P < .01$ ) on admission were more frequently elevated in those patients with CV risk factors. In-hospital mortality was also higher in this subgroup (16 vs 1%;  $P < .01$ ). [Fig. 2](#) shows Kaplan–Meier curves stratified by presence and number of CV risk factors, confirming a significant trend to higher mortality in patients with a greater number of CV risk factors. [Fig. 3](#) shows Kaplan–Meier curves stratified by age and the presence of CVD or CV risk factors. As the figure

**Table 3 – Management and hospital outcomes.**

	Total N = 876	≤ 65 years of age (n = 465, 53%)	> 65 years of age (n = 411, 47%)	P
<i>Hospital admission unit</i>				< .01
Intensive care unit	106 (12)	56 (12)	50 (12)	
Infectious disease ward or similar	675 (77)	328 (71)	347 (84)	
Hospital-at-home program	95 (11)	81 (17)	14 (3)	
<i>Respiratory support</i>				< .01
None	309 (36)	236 (51)	73 (18)	
Nasal cannula or Venturi mask	445 (51)	169 (36)	276 (67)	
High-flow nasal cannula	14 (2)	7 (2)	7 (2)	
Non-invasive ventilation	31 (4)	15 (3)	16 (4)	
Invasive mechanical ventilation	69 (8)	35 (8)	34 (8)	
<i>Prone ventilation</i>	41/69 (59)	21 (60)	20 (58)	.166
<i>Continuous veno-venous hemodiafiltration</i>	7 (0.8)	2 (0.4)	5 (1.2)	.193
<i>Antiviral/antibiotic drugs</i>				
Lopinavir/Ritonavir	115 (13)	43 (9)	72 (18)	< .01
Darunavir/Ritonavir	14 (2)	6 (1)	8 (2)	.440
Darunavir/Cobicistat	14 (2)	3 (1)	11 (3)	.02
Interferon	13 (1)	8 (2)	5 (1)	.538
Remdesivir	4 (0.5)	3 (0.7)	1 (0.2)	.379
Tocilizumab	120 (14)	65 (14)	55 (13)	.798
Hydroxychloroquine	780 (89)	418 (90)	362 (88)	.391
Azithromycin	772 (88)	406 (87)	366 (89)	.427
Ceftriaxone	489 (56)	223 (48)	266 (65)	< .01
<i>Systemic corticosteroid therapy</i>	278 (32)	118 (26)	160 (41)	< .01
<i>Anticoagulation with LMWH</i>				.034
Prophylactic	426 (49)	223 (48)	203 (49)	
Therapeutic	92 (11)	38 (8)	54 (13)	
<i>Length of stay (days)</i>	9 [3–17]	7 [2–13]	11 [4–21]	< .01
<b>In-hospital adverse events</b>				
<i>Death</i>	103 (12)	5 (1)	98 (24)	< .01
Respiratory	95/103 (92)	5/5 (100)	90/98 (92)	
Cardiovascular	7 (7)	0	7 (7)	< .01
Other	1 (1)	0	1 (1)	.265
<i>CHF</i>	33 (4)	7 (2)	26 (6)	.115
<i>Acute coronary syndrome</i>	1 (0.1)	0	1 (0.2)	.026
<i>Cardiogenic shock</i>	2 (0.2)	0	2 (0.5)	.873
<i>Stroke</i>	4 (0.5)	0	4 (1)	.567
<i>Pulmonary embolism</i>	21 (2)	8 (2)	13 (3)	
<i>Long QT-induced arrhythmia</i>	1 (0.1)	0	1 (0.2)	

CHF, congestive heart failure; LMWH, low-molecular-weight heparin.

Data are expressed as n (%), mean ± SD or median [IQR].

**Table 4 – Comparison between patients with and without CVD**

	CVD (n = 135)	No CVD (n = 741)	P
Age, years	77 ± 11	60 ± 18	< .01
Sex, male	87 (64)	395 (54)	.021
ARDS criteria	41 (30)	182 (25)	.162
Need for mechanical ventilation	12 (9)	57 (8)	.635
hs-cTnT elevation on admission	78/100 (78)	148/554 (27)	< .01
NT-proBNP elevation on admission	60/81 (74)	123/425 (29)	< .01
Length of stay, days	8 [2–19]	7 [2–14]	.964
In-hospital death	44 (33)	59 (8)	< .01


ARDS, acute respiratory distress syndrome; hs-cTnT, high-sensitivity cardiac-specific troponin-T; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

Data are expressed as n (%), mean ± SD or median [IQR].


**Table 5 – Comparison between patients with and without CV risk factors**

	CV risk factors (n = 603)	No CV risk factor (n = 273)	P
Age, years	68 ± 16	49 ± 16	< .01
Sex, male	333 (55)	149 (55)	.951
ARDS criteria	167 (28)	56 (21)	.021
Need for mechanical ventilation	57 (9)	12 (4)	< .01
hs-cTnT elevation on admission	210/472 (44)	16/182 (9)	< .01
NT-proBNP elevation on admission	164/383 (43)	19/123 (15)	< .01
Length of stay (days)	8 [3–17]	6 [1–11]	.207
In-hospital death	99 (16)	4 (1)	< .01

ARDS, acute respiratory distress syndrome; hs-cTnT, high-sensitivity cardiac-specific troponin-T; NT-proBNP, N-terminal pro-B-type natriuretic peptide.  
Data are expressed as n (%), mean ± SD or median [IQR].



**Fig. 2 – Kaplan–Meier failure function curves showing the mortality rate stratified by the presence and number of CV risk factors. CV, cardiovascular.**



**Fig. 3 – Kaplan–Meier failure function curves showing the mortality rate stratified by age and presence/absence of cardiovascular disease and CV risk factors. CV, cardiovascular; CVD, cardiovascular disease.**

illustrates, older patients with CVD or CV risk factors had a higher risk of death during admission; followed by the group of older patients without CVD or CV risk factors. There were no differences in mortality in young patients with and without CVD or CV risk factors.

The analysis of predictors of death during admission is shown in Table 6. We found that age over 65 (OR 15; 95%CI, 5–43), CHF (OR 3.27; 95%CI, 1.38–7.72) and CKD (OR, 8.55; 95%CI, 1.47–5.46) were independent predictors of death in our cohort.

### Discussion

With data from a prospective cohort of consecutive patients admitted by COVID-19 infection in our center, we found that (a) patients with previous established CVD or CV risk factors have a higher risk of death during admission by COVID-19; (b) the impact of CV risk factors on mortality in COVID-19 seems to be accumulative, as patients with a greater number of CV risk factors showed higher risk of mortality; (c) there is a relevant interaction between age and CVD and CV risk factors in the context of SARS-CoV-2 infection. The presence of CVD or CV risk factors is not associated with worse outcomes in younger patients with COVID-19 in our cohort. However, in older patients, the presence of CVD or CV risk factors identify a subgroup of patients with high mortality; (d) age > 65 years old, previous history of CHF and CKD are independent predictors of in-hospital mortality in COVID-19.

### CVD and CV risk factors

Previous observational data described worse outcomes in patients with CVD and COVID-19 infection. Guo et al. described a higher mortality in patients with CVD (including hypertension, coronary artery disease and cardiomyopathy) compared to those without CVD in 187 COVID-19 patients in China.<sup>9</sup> Li et al. found a higher prevalence of hypertension, diabetes and CVD among severe COVID-19 patients admitted to the ICU compared with those admitted to non-ICU units.<sup>10</sup> In our cohort, those patients with CVD or CV risk factors had a significantly higher risk of death during hospitalization. Furthermore, those patients with CVD or CV risk factors more frequently showed elevated cardiac biomarkers (both hs-cTnT and NT-proBNP) on admission. Recently, Guo et al. described a higher risk of death in patients with CVD and associated myocardial injury (evaluated by elevation of troponin T) among 187 patients with COVID-19.<sup>9</sup> Although the mechanisms of cardiac injury of SARS-CoV-2 remain not fully understood, several potential mechanisms have been



**Table 6 – Analysis of predictors of death**

	Univariable	Multivariable
> 65 years of age	OR, 28; 95%CI, 12–72; $P < .01$	OR, 15; 95%CI, 4.96–43; $P < .01$
Sex, male	OR, 0.74; 95%CI, 0.49–1.11; $P = .141$	
Hypertension	OR, 5.02; 95%CI, 3.11–8.1; $P < .01$	
Treatment with ACEi	OR, 2.34; 95%CI, 1.49–3.68; $P < .01$	
Treatment with ARBs	OR, 1.7; 95%CI, 0.95–3.06; $P = 0.074$	
Dyslipidemia	OR, 2.66; 95%CI, 1.75–4.04; $P < .01$	
Diabetes mellitus	OR, 4.0; 95%CI, 2.59–6.17; $P < .01$	
Smoking habit	OR, 1.39; 95%CI, 0.89–2.2; $P = .148$	
Obesity (BMI > 30)	OR, 1.24; 95%CI, 0.74–2.08; $P = .423$	
Coronary artery disease	OR, 5.44; 95%CI, 3.09–9.58; $P < .01$	
Congestive heart failure	OR, 10; 95%CI, 5.34–19.51; $P < .01$	OR, 3.27; 95%CI, 1.38–7.72; $P < .01$
Valvular heart failure	OR, 4.24; 95%CI, 1.95–9.23; $P < .01$	
Atrial fibrillation or atrial flutter	OR, 5.66; 95%CI, 3.3–9.71; $P < .01$	
CKD	OR, 8.55; 95%CI, 5.11–14.32; $P < .01$	OR, 2.83; 95%CI, 1.47–5.46; $P < .01$
Stroke	OR, 3.03; 95%CI, 1.58–5.81; $P < .01$	
Peripheral artery disease	OR, 5.64; 95%CI, 2.77–11.49; $P < .01$	
COPD	OR, 2.63; 95%CI, 1.44–4.81; $P < .01$	
Bronchial asthma	OR, 0.88; 95%CI, 0.41–1.89; $P = .754$	
Previous cancer	OR, 2.51; 95%CI, 1.52–4.16; $P < .01$	

Those variables with  $P < .1$  in the univariate analysis were included in the model for multivariable analysis. ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; BMI: body mass index; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; OR; odd ratio CI: confidence interval.

proposed, including direct myocardial damage by the virus, systemic inflammatory response to infection or indirect damage induced by hypoxia.<sup>9</sup> Whether worse outcomes in patients with CVD are mediated by this mostly subclinical cardiac injury remains unknown. On the other hand, most CVD components and CV risk factors failed to show an independent relationship with in-hospital death, with only CHF appearing as an independent predictor. This can be explained by baseline differences between groups of patients with/without CVD and CV risk factors. In our study, patients with CVD and CV risk factors were significantly older. The age difference may explain the increased risk found in these subgroups. With this in mind, we would better consider the presence of CVD and CV risk factors as a risk marker. Furthermore, as Fig. 3 illustrates, it seems that there is an interaction between age and CVD or CV risk factors. The presence of CVD or CV risk factors was not associated with worse outcomes in younger patients. On the contrary, the presence of CVD or CV risk factors in older patients identifies a subgroup with particularly poor prognosis in COVID-19.

### Heart failure and SARS-CoV-2

Infections are a frequent cause of hospitalization in patients with CHF. Alon et al. described respiratory infections as the most frequent focus of infection in patients with CHF.<sup>11</sup> Furthermore, infectious-related admissions, compared with other reasons for admission, seem to be associated with an increased 30-day mortality in patients with CHF.<sup>11</sup> Moreover, in our cohort, previous history of CHF was higher (5 vs 1%) than in previous reports regarding other coronaviruses like Middle East respiratory syndrome coronavirus (MERS-CoV).<sup>12</sup>

### Role of ACEIs and ARBs

The linkage between ACEIs/ARBs and COVID-19 is based on the association between angiotensin-converting enzyme 2 (ACE2) and coronaviruses like SARS-CoV-1 and SARS-CoV-2.<sup>13,14</sup> In these viruses, ACE2 acts as a co-receptor for viral entry in the cell. Initial reports of case series from China reported a higher risk of ARDS and death in patients with hypertension.<sup>15,16</sup> These early data raised concern about a possible harmful effect of ACEIs/ARBs in patients with COVID-19. Several scientific societies, like the Council on Hypertension of the European Society of Cardiology, promptly replied arguing that there was no scientific evidence to suggest that treatment with ACEIs or ARBs should be discontinued in patients with COVID-19. In our study, both ACEIs and ARBs failed to show an independent relationship with an increased risk of death in COVID-19 patients, reassuring about the safety of these therapies in the context of SARS-CoV-2 infection.

### Mortality in COVID-19

Initial reports described a higher risk of death during admission by COVID-19 infection. Zhou et al. described 54 deaths among 191 patients with COVID-19 (28%) admitted at 2 hospitals in Wuhan.<sup>15</sup> Similarly, Wu et al. described 44 deaths among the 201 COVID-19 patients (22%) admitted at 1 institution in Wuhan.<sup>16</sup> In our cohort 103 patients (12%) died during the initial admission. As age has been systematically found as a strong predictor of death in COVID-19, differences in mortality might be explained by differences in age between different cohorts. However, in our cohort, mean age was considerably old (62 years old) and very similar to previous data on retrospective cohorts.

## Limitations

Our work has several limitations that deserve discussion. First of all, due to its observational non-randomized design, we cannot exclude the presence of potential confounders that were not identified. Secondly, despite our protocol included the measurement of both hs-cTnT and NT-proBNP levels at the time of admission, only 75% of patients for hs-cTnT and 58% of patients for NT-proBNP were finally evaluated. Therefore, this may constitute a cause of uncontrolled selection bias. Thirdly, the role of age in the prognosis of COVID-19 may also be a matter of debate. Even if it seems clear that older patients have a worse prognosis in COVID-19, part of this poorer outcomes may be linked to less access of these patients to some therapies that might reduce mortality, as might be the case for mechanical ventilation or new drugs. Although in our cohort, we found no differences between older and younger patients in the indication of mechanical ventilation, we cannot exclude that some older patients with aggressive disease were not selected for mechanical ventilation based on opportunity cost criteria in a situation where healthcare system was on the verge of collapse. Fourthly, most patients in our study required hospital admission. Only a group representing 10% of the total cohort was managed in a hospital-at-home program without hospital admission. Furthermore, milder cases without respiratory compromise and with only minor symptoms may have been managed as outpatients by general practitioners and are not well represented in our cohort.

## Conclusions

In patients admitted with COVID-19, the presence of CVD or CV risk factors is associated with an increased risk of death during hospitalization. We found that older age, history of CHF and CKD are independent predictors of death in COVID-19 patients.

### What is known about the subject?

COVID-19 is an infection that has spread rapidly worldwide. Data from retrospective registries described a potential link between the presence of CVD and CV risk factors with worse outcomes in COVID-19 patients.

### Does it contribute with anything new?

Our prospective data confirm that patients with CVD or CV risk factors have a higher risk of death during admission for COVID-19. The role of CV risk factors on mortality is accumulative (patients with a greater number of CV risk factors showed higher risk of mortality). The presence of CVD or CV risk factors is not associated with worse outcomes in young patients. In older patients, the presence of CVD or CV risk factors identify a high-risk subgroup. We found that age > 65 years old, previous history of CHF and CKD are independent predictors of in-hospital mortality in COVID-19 patients.

## Funding

This project received no financial assistance.

## Conflicts of interest

The authors declare that they have no conflicts of interest.

## Acknowledgments

We would like to thank Isabel Cirera and Julio Pascual for their support and enthusiasm in the development of the project. We also thank Cristina Soler, Paula Cabero, Andrea Sanchez, Cristina Tevar, Yolanda Bartolomé, Camino Fernandez and María Ángeles Miralles for their help with data acquisition and administrative support.

## REFERENCES

- European Centre for Disease Prevention and Control. European Union. COVID-19 situation update worldwide, as of 2 August 2020. Available at: <https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases>. Accessed 02.08.20.
- Ministerio de Sanidad, Consumo y Bienestar Social - Profesionales - Situación actual Coronavirus. Available at: <https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/situacionActual.htm>. Accessed 02.08.20.
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
- World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. Available at: <https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117>. Accessed 05.05.20.
- Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. *N Engl J Med*. 2009;361:858-867.
- Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2016;37:2129-2200.
- Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). *Circulation*. 2018;138:e618-e651.
- Fan E, Brodie D, Slutsky AS. Acute respiratory distress syndrome. *JAMA*. 2018;319:698.
- Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). *JAMA Cardiol*. 2020;5:811-818.
- Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clin Res Cardiol*. 2020;109:531-538.
- Alon D, Stein GY, Korenfeld R, Fuchs S. Predictors and outcomes of infection-related hospital admissions of heart failure patients. *PLOS ONE*. 2013;8:e72476.
- Alqahtani FY, Aleanizy FS, Ali El Hadi Mohamed R, et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. *Epidemiol Infect*. 2019;147:e35.

13. Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? *JAMA*. 2020;323:1769–1770.
14. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–angiotensin–aldosterone system inhibitors in patients with COVID-19. *N Engl J Med*. 2020;382:1653–1659.
15. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395:1054–1062.
16. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med*. 2020;180:934–943.